Granulomatosis With Polyangiitis

5
Pipeline Programs
5
Companies
6
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
1
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 3 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
TAVNEOSApproved
avacopan
Unknown Company
Complement 5a Receptor Antagonist [EPC]oral2021

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
AvacopanPhase 2/31 trial
Active Trials
NCT07176546Not Yet Recruiting30Est. Oct 2030
Genentech
GenentechCA - Oceanside
2 programs
1
ObinutuzumabPhase 2Monoclonal Antibody1 trial
RituximabN/AMonoclonal Antibody1 trial
Active Trials
NCT01613599Completed100Est. Apr 2017
NCT05376319Terminated6Est. May 2024
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
RituximabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT01750697Completed25Est. May 2018
CT
1 program
1
Meperizumab injectionPhase 11 trial
Active Trials
NCT05353179UnknownEst. Oct 2022
Airway Therapeutics
Airway TherapeuticsGA - Marietta
1 program
Airway assessmentN/A1 trial
Active Trials
NCT03182049Withdrawn0Est. May 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
AmgenAvacopan
GenentechObinutuzumab
RocheRituximab
Chia Tai TianQing Pharmaceutical GroupMeperizumab injection
Airway TherapeuticsAirway assessment
GenentechRituximab

Clinical Trials (6)

Total enrollment: 161 patients across 6 trials

NCT07176546AmgenAvacopan

TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

Start: Jul 2026Est. completion: Oct 203030 patients
Phase 2/3Not Yet Recruiting
NCT05376319GenentechObinutuzumab

PR3-AAV Resilient Remission or PRRR

Start: Jun 2023Est. completion: May 20246 patients
Phase 2Terminated
NCT01750697RocheRituximab

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Start: May 2013Est. completion: May 201825 patients
Phase 2Completed
NCT05353179Chia Tai TianQing Pharmaceutical GroupMeperizumab injection

Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers

Start: Jun 2022Est. completion: Oct 2022
Phase 1Unknown
NCT03182049Airway TherapeuticsAirway assessment

Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study

Start: Dec 2020Est. completion: May 20230
N/AWithdrawn
NCT01613599GenentechRituximab

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Start: Jun 2012Est. completion: Apr 2017100 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space